Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

130.40 -0.04 (-0.03%)
Official Closing Price Updated: 1:10 PM EST, Nov 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
52 53 Next >
News headline image
Here's My Favorite High-Dividend ETF to Buy Right Now ↗
Via The Motley Fool
Topics ETFs
News headline image
Trump’s ‘Most Favored Nation’ Drug Plan Likely To Face Pushback, JP Morgan Analysts Say ↗
JPMorgan analysts said President Trump’s "most favored nation" drug pricing order is unlikely to move forward without Congressional support and will likely face legal and industry resistance, limiting... 
Via Stocktwits
Topics ETFs Government Stocks
News headline image
S&P 500, Dow Jones Pharma Stocks Boomerang As Trump Threatens Drug-Price Reform ↗
It's still unclear how President Donald Trump plans to tie drug prices in the U.S. to international prices. 
Via Investor's Business Daily
Topics Government Stocks
News headline image
Protagonist/Johnson & Johnson Partnered Drug Shows Significant Skin Clearance In Pivotal Psoriasis Study ↗
Protagonist and J&J report strong Phase 3 psoriasis data for icotrokinra and unveil potent next-gen IL-17 blocker PN-881 at SID meeting. 
Via Benzinga
News headline image
Earnings Scheduled For April 29, 2025 ↗
 
Via Benzinga
News headline image
Earnings Preview For Novartis ↗
 
Via Benzinga
News headline image
FDA Expands Surprise Inspections At Foreign Drug And Food Facilities, Targets Double Standards In Overseas Manufacturing Oversight ↗
FDA to increase surprise inspections at foreign facilities as U.S. companies pour billions into domestic drug and device manufacturing. 
Via Benzinga
News headline image
BioNTech Appoints Novartis Executive As Finance Chief, Reaffirms 2025 Outlook Focusing on Oncology Expansion ↗
BioNTech's Q1 revenue hit $192 million, beating estimates; company confirms 2025 outlook and names new CFO ahead of oncology-focused expansion. 
Via Benzinga
News headline image
Regulus Downgraded By Analysts After $1.7B Novartis Buyout Offer — Street Sees Limited Upside Ahead ↗
Regulus Therapeutics shares surged after Novartis announced a $1.7 billion acquisition, but analysts downgraded the stock citing limited upside. Retail sentiment remained bullish, with speculation of a... 
Via Stocktwits
Topics Stocks
News headline image
Humana Does Not Alter 2025 Outlook Despite Sales Miss And Medicare Membership Decline ↗
Humana beat Q1 EPS estimates with $11.58, reaffirmed 2025 guidance, and outlined margin goals despite a drop in Medicare Advantage membership. 
Via Benzinga
Topics Earnings
News headline image
Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million ↗
Novartis to buy Regulus for $0.8 billion upfront with potential for $1.7B total based on ADPKD drug milestone; deal set to close in H2 2025. 
Via Benzinga
News headline image
AppLovin Stock Tumbles After Edgewater Research Cuts Estimates Citing Rising Competition ↗
Edgewater noted that the mobile gaming macro environment appears to be decelerating gradually, while competition from both Meta and Alphabet is intensifying. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
Regulus Therapeutics Stock Skyrockets On $1.7B Acquisition Offer From Novartis ↗
According to the terms of the deal, Novartis, through a subsidiary, will initiate a tender offer to acquire all of Regulus' outstanding shares for an initial price of $7.00 per share or $800 million. 
Via Stocktwits
News headline image
Novartis Q1 Earnings Beat Street View, CEO 'Confident' In Delivering Upgraded Guidance ↗
Novartis raises 2025 sales and profit forecast as key drugs drive strong Q1 results; core operating income up 23% to $5.6 billion on higher net sales. 
Via Benzinga
Topics Earnings
News headline image
Novartis Creeps Toward A Breakout On Its Beat-And-Raise ↗
Shares are consolidating and are now trading above their 50-day and 200-day lines. 
Via Investor's Business Daily
News headline image
US Stock Futures Edge Higher Tuesday: Expert Warns Of 'Perfect Volatility Storm' With Major Earnings And Economic Data Due This Week ↗
U.S. stock futures are trading flat on Tuesday early-morning, keeping with the broad index averages on Monday, as markets await clarity and more earnings reports to come in over the course of this... 
Via Benzinga
News headline image
General Motors, Coca-Cola And 3 Stocks To Watch Heading Into Tuesday ↗
 
Via Benzinga
News headline image
Sandoz CEO Richard Saynor Slams Proposal For Europe-Wide List Price For New Medicines, Says Report ↗
Saynor told Reuters that the proposal, put forth by Novartis and Sanofi in a letter to the Financial Times on Wednesday, overlooks the structural drivers of high drug prices in the United States and... 
Via Stocktwits
Topics Government Intellectual Property Lawsuit
News headline image
3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.
See these three top-10 stocks in the pharmaceutical industry that are pledging investment in the United States totalling over $100 billion. 
Via MarketBeat
Topics Artificial Intelligence Economy Government
News headline image
The Smartest International Stock ETF to Buy With $100 Right Now ↗
It could be time for international stocks to shine, making this ETF a must-own. 
Via The Motley Fool
Topics ETFs Economy
News headline image
These 2 Top Dividend Stocks Are Making Moves to Avoid the Impact of Tariffs: Are They Buys? ↗
Via The Motley Fool
Topics Economy Government Lawsuit
News headline image
NOVARTIS AG-SPONSORED ADR (NYSE:NVS) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗
NOVARTIS AG-SPONSORED ADR has a stellar value proposition. NYSE:NVS not only scores well in profitability, solvency, and liquidity but also maintains a very reasonable price point. 
Via Chartmill
News headline image
Roche Plans $50 Billion US Investment Over 5 Years With 12,000 New Jobs ↗
Roche to invest $50 billion in U.S. over five years, adding 12,000+ jobs and expanding manufacturing, R&D, and export capacity across eight states. 
Via Benzinga
News headline image
S&P 500, Nasdaq Futures Rise After Stocks Dip Amid Trump's Jabs At Powell, Strong Yen Gives Nikkei A Volatile Start ↗
U.S. stock futures rose Monday night even as Wall Street had a rough start to the week, amid growing concerns regarding the Federal Reserve's independence, and President Donald Trump's repeated attacks... 
Via Benzinga
Topics Economy Government Stocks
News headline image
3 Momentum Stocks That Could Soar Post-Market Volatility
Three unexpected companies have rallied quickly in the period following tariff-related market turbulence; can they maintain momentum? 
Via MarketBeat
Topics Artificial Intelligence World Trade
News headline image
Food for Thought: Results from a Food Allergy Survey of Caregivers
(BPT) - What is it like for millions of American families managing food allergies? To better understand these experiences, Genentech, a member of the Roche Group, and the Novartis Pharmaceuticals... 
Via Brandpoint
News headline image
2 Dividend Stocks Defying the Tariff-Fueled Market Correction to Buy and Hold Forever ↗
Via The Motley Fool
Topics Government World Trade
News headline image
Novartis Commits $23 Billion To Expand US Manufacturing Over Five Years, Despite Tariffs Uncertainties ↗
Novartis commits $23 billion to expand U.S. manufacturing and R&D with 10 new facilities, aiming to produce all key U.S. medicines domestically and add thousands of jobs. 
Via Benzinga
News headline image
Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline ↗
Trump hints at major tariffs on foreign pharmaceuticals, sparking concerns for Indian suppliers and potential hikes in U.S. drug costs. 
Via Benzinga
Topics Government Supply Chain World Trade
News headline image
Dow Jones, S&P 500 Pharma Names Slammed As New Trump Tariffs Target Drug Imports ↗
Big pharmaceutical names plowed lower Wednesday after Trump on Tuesday said that tariffs would take aim at drug imports. 
Via Investor's Business Daily
Topics Government Stocks World Trade
< Previous 1 2 3 4 5 6 7 8 9
...
52 53 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.